The company reported third-quarter revenue of $4.8 billion, comparable to its first and second-quarter revenue of $4.7 billion and $4.8 billion, respectively.
FDA’s list of AI-enabled device authorizations includes almost 700 devices; 58 are from GE HealthCare – more than any other medical technology company.
.
The global cardiovascular diagnostics market is poised for steady growth over the next decade, according to a new report by Future Market Insights. The market is expected to expand at a compound annual growth rate (CAGR) of 5.1%, increasing in value from US$ 5.9 billion in 2023 to US$ 9.7 billion by 2033. After clos.
The medtech giant signed a contract with BARDA to devise AI-enabled ultrasound technology that helps clinicians triage and diagnose lung pathology and traumatic injury.